BIOLASE (NASDAQ:BIOL) Earns Hold Rating from Analysts at started coverage on shares of BIOLASE (NASDAQ:BIOLGet Rating) in a research report sent to investors on Monday morning. The brokerage issued a hold rating on the medical technology company’s stock.

Other research analysts have also recently issued reports about the stock. Maxim Group started coverage on shares of BIOLASE in a report on Friday, March 18th. They set a buy rating and a $1.50 price objective for the company. Colliers Securities reissued a buy rating on shares of BIOLASE in a report on Tuesday, March 22nd. Finally, Zacks Investment Research raised shares of BIOLASE from a sell rating to a hold rating in a report on Tuesday, January 4th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, BIOLASE presently has a consensus rating of Buy and a consensus price target of $1.75.

Shares of BIOLASE stock opened at $0.31 on Monday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.63 and a current ratio of 3.57. The stock has a market capitalization of $48.33 million, a PE ratio of -2.85 and a beta of 1.39. BIOLASE has a 52-week low of $0.30 and a 52-week high of $0.94. The company has a 50-day simple moving average of $0.35 and a two-hundred day simple moving average of $0.44.

BIOLASE (NASDAQ:BIOLGet Rating) last released its quarterly earnings data on Thursday, March 17th. The medical technology company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). BIOLASE had a negative net margin of 41.23% and a negative return on equity of 62.78%. The firm had revenue of $12.41 million during the quarter. During the same period in the previous year, the firm earned ($0.07) earnings per share. As a group, equities research analysts forecast that BIOLASE will post -0.1 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in BIOL. Millennium Management LLC grew its position in BIOLASE by 5,127.1% during the third quarter. Millennium Management LLC now owns 1,575,605 shares of the medical technology company’s stock valued at $1,007,000 after buying an additional 1,545,462 shares during the period. GSA Capital Partners LLP bought a new stake in BIOLASE during the third quarter valued at approximately $802,000. Essex Investment Management Co. LLC bought a new stake in BIOLASE during the third quarter valued at approximately $511,000. Marshall Wace LLP bought a new position in shares of BIOLASE in the third quarter worth approximately $481,000. Finally, Two Sigma Advisers LP boosted its position in shares of BIOLASE by 643.8% in the third quarter. Two Sigma Advisers LP now owns 387,500 shares of the medical technology company’s stock worth $248,000 after purchasing an additional 335,400 shares during the period. Institutional investors own 14.78% of the company’s stock.

BIOLASE Company Profile (Get Rating)

BIOLASE, Inc is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue.

See Also

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with's FREE daily email newsletter.